Company secures a seasoned entrepreneur for the launch of their innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Dr. Jackson Streeter has accepted to serve on neuropacs’ Board of Directors.
Dr. Streeter comes to neuropacs as the current Director of UF-Innovate/Ventures and a Partner at DeepWork Capital. Previously, he founded the medical technology companies PhotoThera and American Veterinary Laser, and he was the CEO of Banyan Biomarkers. He also served as Senior Vice President of Corporate Development and Strategy at Quanterix (NASDAQ:QRTX) and as the CEO of the Institute for the Commercialization of Public Research. Dr Streeter has had several successful exits of companies he founded or as a C-level executive. Dr. Streeter’s board appointments have included Florida Research Consortium, Governor’s Life Science Task Force for the State of Florida, FBI Counter Terrorism Southeast Working Group, Walter H. Coulter Center Committee at the University of Miami and the Gainesville Chamber of Commerce Board of Directors. In addition, he was the first naval flight surgeon selected as a Top Gun staff instructor in the U.S. Navy. He earned his BS degree in Biology from the University of Nevada Reno and his MD from the University of Nevada School of Medicine. He is the inventor of 20+ patents and author on multiple scientific publications.
“Dr. Streeter brings unparalleled expertise and forward-thinking insights that will prove critical for the strategic rollout of neuropacs’ Parkinson’s diagnostic tool” stated Dr. Martin Handfield, neuropacs’ President and CEO. He added: “one of the most challenging parts of growing a startup is often to surround the management team with visionary Directors that have “the right stuff”. Dr. Streeter is one of those forward-looking individuals in Florida, and we are looking forward to the next stage of growth at neuropacs.”
“I’m thrilled to join the neuropacs team. The company has developed breakthrough medical technology to benefit patients stricken with debilitating neurological conditions. Neuropacs AI-enabled technology neuropacs will enable earlier intervention and improved patient outcomes”, commented Dr. Streeter.
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.